Basilea Pharmaceutica Ltd announces that Toctino (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by Finland's National Agency for Medicines (NAM).
Following the recommendation for regulatory approval under the European decentralized procedure, Toctino received national regulatory approval in Finland. Following the regulatory approval of Toctino in Finland, Basilea will submit a pricing and reimbursement dossier to the Finnish authorities.
Marketing applications for the use of alitretinoin in the treatment of severe chronic refractory hand eczema are also under regulatory review in Canada and in Switzerland.
Toctino (alitretinoin) was developed for the use in adults who have severe CHE that is unresponsive to treatment with potent topical corticosteroids.
Basilea Pharma is headquartered in Basel, Switzerland, and listed on the SWX Swiss Exchange. Basilea's integrated research and development operations are currently focused on new antibacterial and antifungal agents to fight drug resistance and on the development of dermatology drugs.